



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Lirilumab

Cat. No.:	HY-P99208
CAS No.:	1000676-41-4
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research <sup>[1][2]</sup> .								
<b>In Vivo</b>	<p>Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>Rag1KO-Tg KIR mice injected with tumor cells<sup>[2]</sup></td></tr><tr><td>Dosage:</td><td>15 mg/kg</td></tr><tr><td>Administration:</td><td>intravenous injection; 15 mg/kg; once</td></tr><tr><td>Result:</td><td>Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.</td></tr></table>	Animal Model:	Rag1KO-Tg KIR mice injected with tumor cells <sup>[2]</sup>	Dosage:	15 mg/kg	Administration:	intravenous injection; 15 mg/kg; once	Result:	Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.
Animal Model:	Rag1KO-Tg KIR mice injected with tumor cells <sup>[2]</sup>								
Dosage:	15 mg/kg								
Administration:	intravenous injection; 15 mg/kg; once								
Result:	Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.								

### REFERENCES

[1]. Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478.

[2]. Kohrt HE, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014 Jan 30;123(5):678-86.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA